|Videos|July 18, 2014
Checkpoint Inhibitors Under Exploration in RCC
Advertisement
Episodes in this series
For High-Definition, Click
There are several early phase clinical trials assessing PD-1 inhibitors for patients with renal cell carcinoma, notes Nicholas J. Vogelzang, MD. At this point, a clear leader has not yet emerged. Genentech is currently exploring bevacizumab plus their PD-L1 inhibitor MPDL3280A. Additionally, BMS has an advantage by marketing both nivolumab and ipilimumab. With all of the agents under exploration, it is a good time for referring patients to clinical trials, Vogelzang adds.
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The combination nearly doubled the confirmed response rate in the randomized phase 2 portion of HexAgon-HN, with the greatest benefit in HPV-positive disease.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC
4
China’s NMPA Approves Adjuvant T-DXd for HER2+ Early Breast Cancer With Residual Invasive Disease
5